|
|
 |
|
Viewing report
|
|
|
|
Idiopathic Pulmonary Fibrosis - A New Hope
Datamonitor, Aug 2005, Pages: 127
Introduction
Idiopathic pulmonary fibrosis is a devastating, relentlessly progressive and lethal disease for which current therapy is minimally effective. However, several promising anti-fibrotic agents, such as Enbrel (etanercept), are now in clinical trials, which may lead to significant improvements in disease survival and create a new high-value indication, estimated to be worth up to $2 billion annually.
Scope
- Examination of the impact of novel drugs on future treatment, supported by interviews with key opinion leaders
- Assessment of the trends in epidemiology to 2015, including the impact of changing demographics and improvements in diagnosis
- Discussion of the challenges to future clinical trial design, including optimization of patient recruitment and inclusion of novel endpoints
- Case study forecasting the global sales of Enbrel (etanercept) to 2015
Highlights
Idiopathic pulmonary fibrosis has a five-year survival rate of 20%, affecting 218,000 people in the global market, of which 60% or 125,000, are diagnosed. The aging of the population, combined with improvements in diagnosis, will result in a 40% increase in the diagnosed patient population to 146,000 by 2015.
Novel therapies which demonstrate progression-free survival will be initiated at diagnosis rather than limited to those patients with advanced disease, analogous to the treatment of rheumatoid arthritis or a malignancy, and will create an estimated market of up to $2 billion annually.
Future clinical trials should exclude patients with stable minimal to moderate and end-stage disease to ensure maximum response to therapy. The inclusion of acute exacerbation and pharmacoeconomic endpoints is vital, as is ensuring aggressive treatment with a novel drug that does not exacerbate pulmonary infections.
Reasons to Purchase
- Identify the long-term patient potential and market segmentation of Idiopathic pulmonary fibrosis
- Gain insight into the current challenges and commercial opportunities associated with this devastating disease
- Explore the strengths and weaknesses associated with compounds in clinical development
Customers who bought this item also bought
Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?
Stakeholder Opinions: Cystic Fibrosis
Novel Approaches to Diagnosing Pulmonary Diseases
Pulmonary Arterial Hypertension: Diagnosis and Evidence-Based Treatment
Stakeholder Perspectives: Liver Fibrosis/Cirrhosis - Point of No Return?
Pharmaceutical Opinion Leader Management
Managing Chronic Obstructive Pulmonary Disease
Congestive Heart Failure: Opinion Leader Forum Expert's Views and Perspective on Diagnosis,Treatment, Product Performance and Closing the Need Gap
Osteoarthritis and Rheumatoid Arthritis: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Product Performance and Closing the Need Gap
Asthma: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Products, Performance and Closing the Need Gap
Diabetes: Opinion Leader Forum - Expert's Views and Perspectives on Diagnosis, Treatment, Product Performance, and Closing the Need Gap
Prostate Cancer Opinion Leader Forum, 2002
|
|
|
|
